Theoretical study on the interactions between ibrutinib and gold nanoparticles for being used as drug delivery in the chronic lymphocytic leukemia

被引:5
|
作者
Sanchez-Coronilla, Antonio [1 ]
Martin, Elisa, I [2 ]
Jose Fernandez-de-Cordova, Francisco [3 ]
Prado-Gotor, Rafael [4 ]
Hidalgo, Jose [1 ]
机构
[1] Univ Seville, Fac Farm, Dept Quim Fis, E-41012 Seville, Spain
[2] Univ Seville, Fac Quim, Dept Ingn Quim, E-41012 Seville, Spain
[3] CSIC Univ Sevilla, Inst Invest Quim IIQ, Ave Amer Vespucio 49, E-41092 Seville, Spain
[4] Univ Seville, Fac Quim, Dept Quim Fis, E-41012 Seville, Spain
关键词
ibrutinib; Leukemia; Density functional theory; Gold nanoparticle; Electron localization function; Density of states; INITIO MOLECULAR-DYNAMICS; TOTAL-ENERGY CALCULATIONS; ELECTRON LOCALIZATION; INHIBITORS;
D O I
10.1016/j.molliq.2020.113878
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
A theoretical study of the interaction of ibrutinib with both cysteine!methyl-cysteine and gold surface is presented. The interest of ibrutinib is that binds through its acrylamide group with the S atom from Cys481 residue of Bruton-tyrosine-ldnase (BTK) protein and inhibits the maturation of B-lymphocytes. In a first part, the interaction of ibrutinib through its acrylamide group with cysteine/methyl-cysteine is studied in the range of 298 to 315 K to analyse the effect of increasing the temperature in the binding of the drug with the amine-acid. The interaction is favoured at physiologic temperature but its stability decreases at higher temperatures. Thus, in patients with fever the drug may present a lower effectivity and certain amount of free drug in the blood may appear increasing the risk of toxicity for them. In the second part, the interaction of ibrutinib with a gold surface was studied to explore the possibility of using gold nanoparticles as ibrutinib deliverer. The most stable interaction corresponds to the structure with the nitrogen atoms from pyrimidine moiety and from NH2 directly focused over gold atoms keeping acrylamide group of ibrutinib free for joining to BTK. Therefore, according to the theoretical results gold nanoparticles may be used as ibrutinib deliverer. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:7
相关论文
共 46 条
  • [1] Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
    Zhou, Hong
    Hu, Pan
    Yan, Xiyue
    Zhang, Yaping
    Shi, Wenyu
    ONCOTARGETS AND THERAPY, 2020, 13 : 4877 - 4892
  • [2] Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions
    Cho, Hee Jeong
    Baek, Dong Won
    Kim, Juhyung
    Lee, Jung Min
    Moon, Joon Ho
    Sohn, Sang Kyun
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (09) : 819 - 830
  • [3] Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia
    Korkmaz, Mustafa
    Eryilmaz, Melek Karakurt
    Karaagac, Mustafa
    Araz, Murat
    Ceneli, Ozcan
    Artac, Mehmet
    ANTI-CANCER DRUGS, 2022, 33 (08) : 765 - 767
  • [4] A theoretical quest for laetrile drug delivery by neutral, cationic, and anionic gold nanoparticles
    Safaei, Somayeh
    Cheshmehkani, Ameneh
    Kassaee, Mohamad Zaman
    COMPUTATIONAL AND THEORETICAL CHEMISTRY, 2025, 1246
  • [5] Comparative Safety of Ibrutinib Versus Zanubrutinib in Patients With Chronic Lymphocytic Leukemia: A Prospective Cohort Study
    Fan, Fuli
    Liu, Xiaodan
    Su, Zhan
    Li, Saisai
    Wang, Chuanlei
    Wang, Shibo
    Cui, Shuxia
    Yan, Yuting
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
  • [6] Phase I study of ibrutinib in Japanese patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
    Shibayama, Hirohiko
    Teshima, Takanori
    Choi, Ilseung
    Hatake, Kiyohiko
    Sekiguchi, Naohiro
    Yoshinari, Nozomi
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (04) : 179 - 186
  • [7] Drug-drug interactions with protein kinase inhibitors used in chronic myeloid leukemia
    Falcou, L.
    Pajiep, M.
    Despas, F.
    Conte, C.
    Lapeyre-Mestre, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 59 - 60
  • [8] Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study
    Muta, Tsuyoshi
    Masamoto, Yosuke
    Yamamoto, Go
    Kurahashi, Shingo
    Kameoka, Yoshihiro
    Ota, Shuichi
    Matsuki, Eri
    Ozeki, Kazutaka
    Toyama, Takanori
    Takahashi, Naoki
    Kumode, Takahiro
    Aotsuka, Nobuyuki
    Yoshimura, Takuro
    Tamura, Hideto
    Omi, Ai
    Shibayama, Kazuhiro
    Watanabe, Aki
    Isobe, Yasushi
    Kojima, Kensuke
    Takizawa, Jun
    Nagai, Hirokazu
    Suzumiya, Junji
    Aoki, Sadao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 161 - 173
  • [9] Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study
    Pula, Bartosz
    Iskierka-Jazdzewska, Elzbieta
    Dlugosz-Danecka, Monika
    Szymczyk, Agnieszka
    Hus, Marek
    Szeremet, Agnieszka
    Drozd-Sokolowska, Joanna
    Waszczuk-Gajda, Anna
    Zaucha, Jan M.
    Holojda, Jadwiga
    Piszczek, Weronika
    Steckiewicz, Pawel
    Wojciechowska, Malgorzata
    Osowiecki, Michal
    Knopinska-Posluszny, Wanda
    Dudzinski, Marek
    Zawirska, Daria
    Subocz, Edyta
    Halka, Janusz
    Pluta, Andrzej
    Wichary, Ryszard
    Kumiega, Beata
    Budziszewska, Bozena K.
    Jurczak, Wojciech
    Lech-Maranda, Ewa
    Giannopoulos, Krzysztof
    Robak, Tadeusz
    Jamroziak, Krzysztof
    ANTICANCER RESEARCH, 2020, 40 (07) : 4059 - 4066
  • [10] Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
    Mato, A. R.
    Hill, B. T.
    Lamanna, N.
    Barr, P. M.
    Ujjani, C. S.
    Brander, D. M.
    Howlett, C.
    Skarbnik, A. P.
    Cheson, B. D.
    Zent, C. S.
    Pu, J. J.
    Kiselev, P.
    Foon, K.
    Lenhart, J.
    Bachow, S. Henick
    Winter, A. M.
    Cruz, A. -L.
    Claxton, D. F.
    Goy, A.
    Daniel, C.
    Isaac, K.
    Kennard, K. H.
    Timlin, C.
    Fanning, M.
    Gashonia, L.
    Yacur, M.
    Svoboda, J.
    Schuster, S. J.
    Nabhan, C.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1050 - 1056